Shizuoka, Japan

Shinya Ishii

This inventor holds 14 USPTO granted patents and 27 published patent applications, plus 2 CIPO patents and 11 EPO patents, primarily in Antigen-Binding Molecules. Top assignee: Chugai Seiyaku Kabushiki Kaisha. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shinya Ishii. Retrieved from https://idiyas.com/inventor/shinya-ishii-x7t3yil1

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 14 

% Patents Active = 92.9

 

 

Average Co-Inventor Count = 3.7

ph-index = 6

Forward Citations = 216(Granted Patents)


Location History:

  • Singapore, SG (2023)
  • Shizuoka, JP (2013 - 2024)

Company Filing History:


Years Active: 2013-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Antigen-Binding Molecule
Cytotoxicity
IL-6 Activity
Therapeutic Agent
Binding Molecule Library
Claudin-6
Modified Helper Phage
Disease Treatment
14 patents (USPTO):Explore Patents

Title: Innovations by Inventor Shinya Ishii

Introduction

Shinya Ishii, a distinguished inventor based in Shizuoka, Japan, holds an impressive portfolio with 12 patents to his name. His groundbreaking work primarily focuses on the development of antigen-binding molecules, which have significant implications for therapeutic applications, particularly in treating various cancers.

Latest Patents

Ishii's latest patents include an innovative antigen-binding molecule capable of binding to a plurality of antigen molecules repeatedly. The objective of this invention is to enhance methods for promoting antigen uptake into cells. It also aims to increase the frequency of antigen binding by a single molecule and facilitate the reduction of antigen concentration in plasma. Furthermore, these antigen-binding molecules are designed to improve plasma retention, offering several pharmaceutical compositions and production methods.

Another notable patent addresses a cytotoxicity-inducing therapeutic agent. This invention reveals novel multispecific antigen-binding molecules that demonstrate excellent cellular cytotoxicity. These molecules comprise a first domain binding to DLL3 and a second domain connecting to the T cell receptor complex. The development of bispecific antibodies shows strong T cell-dependent cellular cytotoxicity (TDCC), making these compositions promising candidates for treating cancers associated with DLL3.

Career Highlights

Shinya Ishii works with Chugai Seiyaku Kabushiki Kaisha, a prominent pharmaceutical company known for its commitment to innovative healthcare solutions. His contributions to the field of antibody development and cellular therapies mark significant advancements in medical science.

Collaborations

Throughout his career, Ishii has collaborated with notable colleagues such as Tomoyuki Igawa and Atsuhiko Maeda. These partnerships have facilitated the successful exploration of complex molecular interactions and the advancement of new therapeutic methodologies.

Conclusion

With a robust number of patents and a clear focus on innovative therapeutic solutions, Shinya Ishii continues to contribute significantly to the fields of biotechnology and pharmaceuticals. His work not only enhances our understanding of antigen-binding molecules but also paves the way for future advancements in cancer treatment.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…